Fannin

Fannin Ltd Named Exclusive Distributor in Ireland for MyBio Self Testing Kits

Retrieved on: 
Wednesday, May 3, 2023
Health, Medical Supplies, Medical Devices, Linda, Fannin, Partnership, Ovulation, Pharmacy, International business development, Menopause, Built-in self-test, Woman, LTD, Fertility, Pharmacist, Male, International business, Prostate-specific antigen, Birth control, Pregnancy

Fannin Ltd, Dublin, Ireland announced a strategic partnership with MyBio™, Kilkenny, Ireland aimed at providing the opportunity for people to take more responsibility for their own health.

Key Points: 
  • Fannin Ltd, Dublin, Ireland announced a strategic partnership with MyBio™, Kilkenny, Ireland aimed at providing the opportunity for people to take more responsibility for their own health.
  • Founded in 2009 by Dr Linda Nolan, MyBio™ is a leading supplier of life science, diagnostic, and wellness products.
  • Since 2020, MyBio™ has become a market leader in the supply of antigen self-testing kits across Ireland, the UK and Europe.
  • Patrick Tehan, General Manager of Pharma Ireland: “We are very pleased to be partnering with MyBio™ to bring their range of MyBio™ self-testing kits to retail pharmacies in Ireland.

Pulmotect Provides Results from Two Randomized, Placebo Controlled Phase-2 Trials of PUL-042 Against COVID-19

Retrieved on: 
Thursday, December 2, 2021
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Patient, U.S. Department of Defense Strategy for Operating in Cyberspace, Cancer prevention, World Health Organization, CEO, Technology, Research institute, MCDC, MERS, Pandemic, Immunodeficiency, PCR, Studio, World, Army, Severe acute respiratory syndrome coronavirus 2, Virus, Severity, UT, D, Efficacy, Urinary tract infection, Infection rate, Epidemic, Cough, COVID-19, Animal, National, Cancer Prevention and Research Institute of Texas, NIAID, Medicine, ROS, Safety, Data lake, Incidence, Radiation, Reactive oxygen species, SARS, Degenerative disease, Immune system, Fannin, Command, OSCI, DOD, Fatigue, Epithelium, Pharmaceutical industry, Vaccine, PUL-042, Pulmotect, Fannin Innovation Studio, PUL-042, PULMOTECT, FANNIN INNOVATION STUDIO

Results from these trials support the potential of PUL-042 in reducing the severity of COVID-19.

Key Points: 
  • Results from these trials support the potential of PUL-042 in reducing the severity of COVID-19.
  • We now have data from over 200 subjects treated with PUL-042, said Dr. Colin Broom, CEO of Pulmotect.
  • Subjects were tested for SARS-CoV-2 using a nasopharyngeal PCR test at study enrollment and again after 15 and 28 days.
  • All three PUL-042 treated subjects cleared virus by Day 15 of the trial compared to none of the three placebo treated subjects.

Pulmotect Reports Positive Topline Results from Randomized, Placebo Controlled Phase-2 Trial of PUL-042 against COVID-19

Retrieved on: 
Friday, September 24, 2021
Health, Infectious Diseases, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Epidemic, Safety, Animal, DOD, MERS, Radiation, National, Patient, Fatigue, Pandemic, World, Data lake, Health, Reactive oxygen species, JPM, Research institute, ROS, World Health Organization, Population, Cough, Virus, Command, Cancer prevention, CEO, Severity, UT, Immunodeficiency, Efficacy, Fannin, Army, MCDC, COVID-19, Degenerative disease, Severe acute respiratory syndrome coronavirus 2, SARS, D, Incidence, NIAID, Studio, Medicine, Time, Epithelium, Urinary tract infection, Cancer Prevention and Research Institute of Texas, Pharmaceutical industry, Vaccine, PUL-042, Pulmotect, Fannin Innovation Studio, PUL-042, PULMOTECT, FANNIN INNOVATION STUDIO

Inhaled PUL-042 stimulates the lungs innate immune system with the potential to protect against a wide variety of respiratory pathogens.

Key Points: 
  • Inhaled PUL-042 stimulates the lungs innate immune system with the potential to protect against a wide variety of respiratory pathogens.
  • PUL-042 could be directed against all existing and future variants of the SARS-CoV-2 virus, as well as future pandemics.
  • Based on the promising results from this trial and remarkable activity in pre-clinical models, PUL-042 also has potential for use in other patient populations.
  • The median time to improvement of respiratory symptoms was 6 days for PUL-042 and 9 days for placebo.